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Background/aims: A large proportion of men with normal sperm results as analyzed 
using conventional techniques have fragmented DNA in their spermatozoa. We per-
formed a prospective study to examine the incidence of DNA fragmentation in sperm 
in cases of couples with previously unexplained infertility and treated with intrauterine 
insemination. We evaluated whether there was any predictive value of DNA fragmenta-
tion for pregnancy outcome in such couples.
Methods: The percentage of DNA fragmentation and all classical variables to evaluate 
sperm before and after sperm treatment were determined. We studied the probable 
association between these results and pregnancy outcome in terms of clinical and 
ongoing pregnancy rate per started first cycle. We also assessed the optimal threshold 
level to diagnose DNA fragmentation in our center.
results: When using threshold levels of 20, 25, and 30%, the occurrence of DNA frag-
mentation was 42.9, 33.3, and 28.6%, respectively. Receiver operating characteristic 
(ROC) analysis of all cases revealed an area under the curve of 80% to predict the clinical 
pregnancy rate per cycle from testing the sperm motility (a + b) before treatment. We 
failed to generate an ROC curve to estimate pregnancy outcome from the amount of 
DNA fragmentation before treatment. However, when selecting only those men with a 
pretreatment DNA fragmentation of at least 20%, the pretreatment result was statistically 
different between couples who achieved a clinical pregnancy and those who did not.
conclusion: DNA fragmentation is often diagnosed in couples with unexplained infertil-
ity. Each center should evaluate the type of test it uses to detect DNA fragmentation in 
sperm and determine its own threshold values.
Keywords: Dna fragmentation, chromatin dispersion test, oxygen radicals, in vitro fertilization, receiver operating 
characteristic
FigUre 1 | interpretation of the halosperm test.
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inTrODUcTiOn
Recent research has revealed that subtle abnormalities can be 
found in sperm samples that seem to be normal according to 
conventional analysis techniques (1, 2). The DNA in the sperm 
head is sometimes fragmented, and this may be the reason why 
couples with a diagnosis of unexplained infertility do not achieve 
pregnancy. There seems to be a correlation between sperm frag-
mentation and aneuploidy (3).
DNA damage in spermatozoa affects both mitochondrial 
and nuclear DNA (4). Its origin can be explained by six main 
mechanisms:
 – apoptosis during the process of spermatogenesis;
 – DNA strand breaks that occur during the remodeling of sperm 
chromatin in spermatogenesis;
 – post-testicular DNA fragmentation induced mainly by oxy-
gen radicals (ROS), including the hydroxyl radical and nitric 
oxide, during sperm transport through the seminiferous 
tubules and the epididymis; the effect of ROS on sperm has 
been known since 1943 (5);
 – DNA fragmentation induced by endogenous caspases and 
endonucleases;
 – DNA damage induced by radiotherapy and chemotherapy; and
 – DNA damage induced by environmental toxicants.
Fifteen percent of men with normal basic semen analysis 
profiles (6) have been associated with infertility problems (7). 
Moreover, about 8% of men with normal sperm results do have 
abnormal levels of DNA fragmentation in sperm (8).
Most studies of prognostic factors for pregnancy with intrau-
terine inseminations (IUI) focus on the motility of the sperm after 
treatment. A total motile count of 1–2 million sperm cells is usu-
ally regarded as a threshold value to obtain a pregnancy in cases of 
unexplained or mild male infertility (9). More recent studies have 
provided evidence for the inverse relationship between clinical 
outcomes of IUI and the amount of DNA fragmentation (8).
We planned a prospective observational study to examine the 
incidence of DNA fragmentation in sperm in cases of couples 
with previously unexplained infertility. We assumed that DNA 
fragmentation was likely to be present in sperm for a number of 
couples with the so-called unexplained infertility. We also selected 
this group of patients to exclude as many confounding diagnostic 
factors as possible. In the first treatment cycle with IUI, the per-
centage of DNA fragmentation in sperm was measured before and 
after sperm preparation. We evaluated if there was any predictive 
value of DNA fragmentation for pregnancy outcome. Afterward, 
the results of pregnant patients were compared with those who 
were not, for different threshold levels of DNA fragmentation.
MaTerials anD MeThODs
This prospective study was approved by the Ethical Committee 
of Ghent University Hospital and internationally (http://
ClinicalTrials.gov approval number: NCT02235103). Between 
March 1, 2014 and February 1, 2016, we recruited 25 patients. 
Study enrollment depended on the availability of laboratory 
facilities on a daily basis. A written and informed consent was 
obtained from all participants.
We included only first treatment cycles of couples with 
unexplained infertility. Female patients were checked for tubal 
patency by hysterosalpingography or hysterosalpingo-foam 
sonography (10, 11) or by laparoscopy if indicated. Their cycles 
were documented as ovulatory. Uterine and ovarian abnormali-
ties were excluded by clinical and ultrasound examination. All 
the included female patients were between 18 and 40 years old.
A sperm analysis was performed before treatment and 
revealed no abnormalities according to the WHO criteria (12). 
Diagnostic sperm analysis was carried out using the automated 
SCA® system (Sperm Class Analyser, CASA System, Microptics, 
Barcelona, Spain). Morphology assessment was done manually 
using Spermblue® staining (Microptics).
According to our protocol and evidence-based guidelines 
(13), the patients were treated by ovarian stimulation (50-mg 
clomiphene citrate starting from cycle day 3, for five consecutive 
days) and IUI. Monitoring was performed lege artis (14).
On the day of treatment, semen specimens were collected by 
masturbation into sterile cups. Semen was allowed to liquefy for 
30 min, and an aliquot was taken for macroscopic and microscopic 
assessments. Specimens were assessed for volume, count, motility, 
and morphology. The first assessment of DNA fragmentation was 
carried out at this time. Of the various tests currently available for 
determining DNA fragmentation, we selected the sperm chro-
matin dispersion (SCD) test (Halosperm®; Halotech, Madrid, 
Spain). The SCD test assesses the capacity of the sperm chromatin 
to disperse, under the effect of hydrochloric acid to denature 
the chromatin, and to generate restricted single-stranded DNA 
motifs from DNA. After denaturing, a lysing solution was used, 
and the level of DNA fragmentation was estimated by the size of 
the nuclear dispersion and measured using immunofluorescence 
or optical microscopy (Figure  1). The amount of dispersion is 
inversely proportional to the level of DNA damage (8).
TaBle 1 | Descriptive statistics.
Variable
Number of patients 21
Female age (years) 33.8 (4.1)
Female body mass index (kg/m2) 23.0 (4.2)
Duration of infertility (years) 2.2 (1.3)
Anti-Müllerian hormone (ng/mL) 2.5 (1.5)
Male age (years) 35.8 (8.2)
Male body mass index (kg/m2) 25.7 (3.6)
Sperm concentration (×106/mL) 72.7 (40.5)
Sperm motility a + b (%) 52.8 (13.5)
Normal sperm morphology (%) 6.8 (3.8)
Sperm motility pre a + b (%) 46.1 (17.4)
Total motile count pre (×106) 86.3 (62.2)
Normal sperm morphology pre (%) 8.0 (3.9)
DNA fragmentation pre (%) 22.0 (12.1)
Total motile count post (×106) 27.9 (23.8)
DNA fragmentation post (%) 6.3 (5.9)
DNA fragmentation difference (%) 68.5 (35.7)
Clinical pregnancy rate per cycle (%) 23.8
Ongoing pregnancy rate per cycle (%) 19.0
Numbers are expressed as means (SD) unless explained differently.
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Sperm preparation was performed using a two-layer (90 
and 45%) percoll gradient supplied by Cook® (Cook, Limerick, 
Ireland) with centrifugation at 400 × g for 20 min. The procedure 
is described in more detail elsewhere (15). After this capacita-
tion procedure, a diagnostic sperm evaluation, except for the 
morphology assessment and the SCD assay, was repeated on an 
aliquot. IUI followed without delay because shortening the time 
period between semen processing and insemination minimizes 
sperm DNA fragmentation (4).
The outcome variables studied were the clinical pregnancy rate 
and the ongoing pregnancy rate per started cycle as defined by the 
WHO criteria (16).
We used receiver operating characteristic (ROC) curve analysis 
for testing the sensitivity and specificity of different sperm vari-
ables in predicting the pregnancy outcome. Sperm concentration, 
motility, and morphology, as well as DNA fragmentation before 
and after sperm preparation and the percentage amelioration 
(difference) of DNA fragmentation after sperm preparation, were 
included in the analysis.
Filtering the data for different cut-off levels of sperm DNA 
fragmentation allowed us to see if there were any differences in 
sperm variables between the pregnant and non-pregnant groups 
in these different cohorts. All analyses were performed for clinical 
and ongoing pregnancies as outcome variables. A cut-off level of 
30% is usually cited in the literature for the SCD assay (17). We 
used 20, 25, and 30% as cut-off levels for our analysis.
Statistical analysis was performed using the SPSS V23. Fisher’s 
exact test was applied for proportions and the non-parametric 
Mann–Whitney U test for continuous outcomes. p Values <0.05 
were considered statistically significant.
resUlTs
Although 25 patients were originally intended for inclusion, only 
21 could be retained for further analysis. Three patients were 
excluded because of a lack of weekend laboratory facilities, and 
one was excluded because of missing data regarding the male 
history.
Patient characteristics are summarized in Table 1. Only cases 
of unexplained male and female subfertility were included, as 
illustrated by normal values for the diagnostic sperm analysis. The 
distribution curve of the values obtained with the pretreatment 
DNA fragmentation test is illustrated in Figure 2. Nine patients 
(42.9%) showed an abnormal level of DNA fragmentation at a 
cut-off level of 20%. At the level of 25 and 30%, the numbers were 
7 (33.3%) and 6 (28.6%), respectively.
The results of DNA fragmentation tests before and after treat-
ment, as well as the DNA fragmentation differences for individual 
patients, are summarized in Table 2.
Receiver operating characteristic curve analysis was per-
formed for the following sperm variables to test their specificity 
and sensitivity in predicting clinical pregnancy rate and ongoing 
pregnancy rate per started cycle, respectively:
 – sperm concentration, motility (a + b), and normal morphol-
ogy in the diagnostic sample;
 – motility (a + b), total motile count, normal morphology, and 
DNA fragmentation in the native sample before capacitation;
 – motility (a + b), total motile count, and DNA fragmentation 
in the treated sample; and
 – percentage of amelioration of DNA fragmentation in the 
treated sample.
The ROC curve on motility (a + b) before treatment to estimate 
the probability of clinical pregnancy per treatment cycle was the 
only parameter that satisfied the statistical requirements. The area 
under the curve AUC was 80% [95% confidence interval (CI): 
61–99%; p < 0.05] (Figure 3).
None of the DNA fragmentation variables fulfilled the statisti-
cal criteria to be considered useful. Either the AUC was too low 
(<70%) or the association was insignificant (p ≥ 0.05).
The association between the pregnancy rates per cycle and 
the degree of pretreatment DNA fragmentation (Figure 4) was 
analysed by calculating the clinical and ongoing pregnancy rates 
per started cycle for different patient cohorts. When filtering 
the results for patients with minimum levels of 20, 25, and 30% 
DNA fragmentation, respectively, the difference between the 
≥20% group and those with higher levels of DNA fragmenta-
tion was striking, although not statistically significant (Fisher’s 
exact test).
When comparing the degree of amelioration of DNA frag-
mentation between the entire patient group and those with a 
pretreatment level of DNA fragmentation of ≥20%, again, we 
found no differences in pregnancy rates (Figure 5).
After filtering the data for patients with a pretreatment 
DNA fragmentation of 20%, all previously mentioned sperm 
variables were analyzed for equality between the pregnant and 
non-pregnant patients, both for clinical and ongoing pregnan-
cies. Because of the unequal variances, a Mann–Whitney U test 
was performed. The same evaluation was performed after filtering 
data for patients with a pretreatment DNA fragmentation value 
of ≥25 and ≥30%.
TaBle 2 | individual data on Dna fragmentation.
Patient 
number
Dna fragmentation 
pre (%)
Dna fragmentation 
post (%)
Dna fragmentation 
difference (%)
1 50.0 10.5 79.0
2 22.5 22.0 2.2
3 18.0 1.5 91.7
4 33.5 15.5 53.7
5 30.0 4.5 85.0
6 30.0 3.5 88.3
7 8.5 5.0 41.2
8 15.0 0.0 100.0
9 12.0 3.5 70.8
10 21.5 5.5 74.4
11 8.5 13.0 −52.9
12 34.0 15.0 55.9
13 12.0 2.0 83.3
14 15.0 1.0 93.3
15 10.0 1.0 90.0
16 28.0 7.5 73.2
17 49.0 9.0 81.6
18 14.0 4.5 67.9
19 15.0 0.5 96.7
20 17.5 1.5 91.4
21 18.0 5.0 72.2
FigUre 2 | Distribution curve of Dna fragmentation before treatment.
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The only significant finding was a difference in the percentage 
of pretreatment DNA fragmentation between patients who were 
clinically pregnant vs. those who were not and who already had a 
pretreatment value of ≥20% (Figure 6).
DiscUssiOn
Various assays have been developed to measure either the propor-
tion of spermatozoa displaying DNA fragmentation in a sperm 
sample or the DNA damage per spermatozoon (8). Examples 
of the former are the sperm chromatin structure assay (SCSA), 
SCD, and terminal deoxynucleotidyl transferase-mediated dUTP 
nick-end labeling (TUNEL) tests. The Comet test (single-cell 
gel electrophoresis) belongs to the latter category. Despite their 
variability in protocol, comparative studies have shown close 
correlations between DNA damage measured by these different 
commonly used assays (7). Our choice for SCD was made from 
a practical point of view: simplicity, cost-effectiveness, reproduc-
ibility, and lack of requirement for special equipment.
The debate on the routine use of testing for the degree of 
DNA fragmentation in sperm is ongoing (18). Nowadays, most 
reports provide evidence for a negative impact of elevated DNA 
fragmentation on the clinical outcome of treating couples by 
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means of timed intercourse or IUI (8). However, its relevance in 
in vitro fertilization (IVF) and intra-cytoplasmic sperm injection 
(ICSI) remains more elusive. A recent meta-analysis revealed a 
higher live birth rate in IVF-treated couples with low DNA frag-
mentation; a sensitivity analysis showed no difference when ICSI 
was used (19). The type of assay may also be important. When 
FigUre 3 | receiver operating characteristic (rOc) curve to test the sensitivity and the specificity of the sperm motility a + b before treatment to 
predict the clinical pregnancy rate per cycle. The area under the curve (AUC) is 80% (95% CI: 61–99%); p < 0.05.
FigUre 4 | association between the pregnancy rates per cycle and the degree of Dna fragmentation pretreatment.
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FigUre 6 | association between clinical pregnancy and the degree of pretreatment Dna fragmentation in unselected patients (ns) and patients with 
a pretreatment Dna fragmentation of ≥20% (p < 0.05).
FigUre 5 | comparison of the degree of Dna fragmentation difference and the clinical and ongoing pregnancy outcome between all patients and 
those with a pretreatment Dna fragmentation of ≥20%.
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